Today, Alexion Pharmaceuticals Inc. (ALXN) Stock Rating Upgrade by Vetr Inc.

Today, Alexion Pharmaceuticals Inc. (ALXN) Stock Rating Upgrade by Vetr Inc.

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) was upgraded by investment analysts at Vetr from a “hold” rating to a “buy” rating in a report issued on Monday. The brokerage currently has a $142.00 price target on the biopharmaceutical company’s stock. Vetr‘s target price indicates a potential upside of 19.50% from the stock’s current price.

A number of other equities research analysts also recently issued reports on ALXN. Credit Suisse Group AG raised shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating and reduced their price objective for the stock from $186.00 to $165.00 in a research report on Monday, July 11th. They noted that the move was a valuation call. Royal Bank Of Canada initiated coverage on shares of Alexion Pharmaceuticals in a research report on Tuesday, July 12th. They issued an “outperform” rating and a $188.00 price objective for the company. SunTrust Banks Inc. reduced their price objective on shares of Alexion Pharmaceuticals from $220.00 to $197.00 and set a “buy” rating for the company in a research report on Wednesday, July 13th. Leerink Swann reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Alexion Pharmaceuticals in a research report on Sunday, July 17th. Finally, Jefferies Group reaffirmed a “hold” rating and issued a $140.00 price objective (down from $159.00) on shares of Alexion Pharmaceuticals in a research report on Monday, July 25th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. Alexion Pharmaceuticals has an average rating of “Buy” and a consensus price target of $173.36.

Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 0.08% during midday trading on Monday, hitting $118.83. 472,545 shares of the stock were exchanged. Alexion Pharmaceuticals has a 1-year low of $110.56 and a 1-year high of $193.45. The firm has a market capitalization of $26647.39 billion, a P/E ratio of 289.83 and a beta of 1.45. The firm’s 50-day moving average price is $122.72 and its 200 day moving average price is $129.05.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.04 by $0.19. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The business earned $799 million during the quarter, compared to the consensus estimate of $787.07 million. During the same period in the prior year, the firm posted $1.16 EPS. The firm’s quarterly revenue was up 19.9% compared to the same quarter last year. Analysts expect that Alexion Pharmaceuticals will post $4.64 earnings per share for the current fiscal year.

In related news, Director Leonard Bell sold 37,317 shares of the stock in a transaction on Friday, November 4th. The shares were sold at an average price of $140.38, for a total transaction of $5,238,560.46. Following the transaction, the director now owns 440,936 shares of the company’s stock, valued at approximately $61,898,595.68. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Clare Carmichael sold 1,000 shares of the stock in a transaction on Tuesday, August 30th. The shares were sold at an average price of $127.76, for a total transaction of $127,760.00. Following the transaction, the executive vice president now directly owns 38,577 shares in the company, valued at approximately $4,928,597.52. The disclosure for this sale can be found here. Corporate insiders own 4.41% of the company’s stock.

Large investors have recently made changes to their positions in the company. Baker BROS. Advisors LP purchased a new stake in shares of Alexion Pharmaceuticals during the third quarter worth about $801,815,000. FMR LLC raised its stake in shares of Alexion Pharmaceuticals by 12.0% in the second quarter. FMR LLC now owns 18,745,795 shares of the biopharmaceutical company’s stock worth $2,188,759,000 after buying an additional 2,002,085 shares during the period. BlackRock Investment Management LLC raised its stake in shares of Alexion Pharmaceuticals by 177.0% in the third quarter. BlackRock Investment Management LLC now owns 2,243,677 shares of the biopharmaceutical company’s stock worth $274,940,000 after buying an additional 1,433,769 shares during the period. BlackRock Advisors LLC raised its stake in shares of Alexion Pharmaceuticals by 130.7% in the third quarter. BlackRock Advisors LLC now owns 2,286,891 shares of the biopharmaceutical company’s stock worth $280,236,000 after buying an additional 1,295,520 shares during the period. Finally, TIAA CREF Investment Management LLC raised its stake in shares of Alexion Pharmaceuticals by 34.8% in the second quarter. TIAA CREF Investment Management LLC now owns 2,952,205 shares of the biopharmaceutical company’s stock worth $344,699,000 after buying an additional 762,010 shares during the period. 96.55% of the stock is currently owned by institutional investors and hedge funds.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Related posts

Leave a Comment